BMO Capital Markets began coverage on shares of Inflarx (NASDAQ:IFRX) in a research note published on Friday, July 13th, MarketBeat.com reports. The brokerage issued an outperform rating and a $45.00 price objective on the stock.
IFRX has been the subject of several other reports. ValuEngine upgraded Inflarx from a sell rating to a hold rating in a report on Wednesday, May 2nd. Zacks Investment Research downgraded Inflarx from a hold rating to a sell rating in a report on Saturday, April 7th. Raymond James assumed coverage on Inflarx in a report on Thursday, June 28th. They issued an outperform rating and a $44.00 price objective for the company. Leerink Swann reiterated an outperform rating and issued a $42.00 price objective on shares of Inflarx in a report on Friday, May 18th. Finally, SunTrust Banks initiated coverage on Inflarx in a report on Thursday, June 28th. They issued a buy rating and a $55.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $42.67.
Shares of Inflarx stock opened at $31.52 on Friday. The firm has a market cap of $784.23 million and a price-to-earnings ratio of -10.72. Inflarx has a 12 month low of $14.47 and a 12 month high of $42.83.
Inflarx (NASDAQ:IFRX) last posted its quarterly earnings results on Thursday, May 17th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.06). equities research analysts forecast that Inflarx will post -1.66 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in IFRX. Barclays PLC bought a new position in shares of Inflarx during the 1st quarter valued at approximately $144,000. Amundi Pioneer Asset Management Inc. bought a new position in shares of Inflarx during the 4th quarter valued at approximately $126,000. Northern Trust Corp bought a new position in shares of Inflarx during the 1st quarter valued at approximately $228,000. Schwab Charles Investment Management Inc. bought a new position in shares of Inflarx during the 1st quarter valued at approximately $367,000. Finally, Birchview Capital LP bought a new position in shares of Inflarx during the 2nd quarter valued at approximately $516,000. Institutional investors and hedge funds own 41.80% of the company’s stock.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Further Reading: Penny Stocks, What You Need To Know
Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.